Literature DB >> 26099672

PET/Computed Tomography in Renal, Bladder, and Testicular Cancer.

Kirsten Bouchelouche1, Peter L Choyke2.   

Abstract

Imaging plays an important role in the clinical management of cancer patients. Hybrid imaging with PET/computed tomography (CT) is having a broad impact in oncology, and in recent years PET/CT is beginning to have an impact in urooncology. In both bladder and renal cancers, there is a need to study the efficacy of other tracers than F-18 fluorodeoxyglucose (FDG), particularly tracers with limited renal excretion. Thus, new tracers are being introduced. This review focuses on the clinical role of FDG and other PET agents in renal, bladder, and testicular cancers. Published by Elsevier Inc.

Entities:  

Keywords:  Bladder cancer; PET/CT; Renal cancer; Testicular cancer

Mesh：

Substances：

Year:  2015        PMID： 26099672      PMCID： PMC4479416          DOI： 10.1016/j.cpet.2015.03.002

Source DB:  PubMed          Journal:  PET Clin        ISSN： 1556-8598


  82 in total

1.  Is fluorine-18 fluorodeoxyglucose positron emission tomography useful for detecting bladder lesions? A meta-analysis of the literature.

Authors:  Ningjian Wang; Peng Jiang; Yingli Lu
Journal:  Urol Int       Date:  2013-08-08       Impact factor: 2.089

2.  Differentiation of seminomatous from nonseminomatous testicular tumors with MR imaging.

Authors:  J O Johnson; R F Mattrey; J Phillipson
Journal:  AJR Am J Roentgenol       Date:  1990-03       Impact factor: 3.959

3.  Can we rely on PET in the follow-up of advanced seminoma patients?

Authors:  Jerzy Siekiera; Bogdan Małkowski; Wojciech Jóźwicki; Miłosz Jasiński; Andrzej Wronczewski; Tomasz Pietrzak; Ewa Chmielowska; Andrzej Petrus; Krzysztof Kamecki; Witold Mikołajczak; Krzysztof Kraśnicki; Piotr Chłosta; Tomasz Drewa
Journal:  Urol Int       Date:  2012-04-12       Impact factor: 2.089

4.  Diagnostic efficacy of [11C]choline positron emission tomography/computed tomography compared with conventional computed tomography in lymph node staging of patients with bladder cancer prior to radical cystectomy.

Authors:  Tobias Maurer; Michael Souvatzoglou; Hubert Kübler; Katharina Opercan; Stefan Schmidt; Ken Herrmann; Jens Stollfuss; Gregor Weirich; Bernhard Haller; Jürgen E Gschwend; Markus Schwaiger; Bernd J Krause; Uwe Treiber
Journal:  Eur Urol       Date:  2011-12-14       Impact factor: 20.096

Review 5.  Nuclear medicine studies of the prostate, testes, and bladder.

Authors:  Suman Jana; M Donald Blaufox
Journal:  Semin Nucl Med       Date:  2006-01       Impact factor: 4.446

6.  Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma.

Authors:  M De Santis; C Bokemeyer; A Becherer; F Stoiber; K Oechsle; K Kletter; B M Dohmen; C Dittrich; J Pont
Journal:  J Clin Oncol       Date:  2001-09-01       Impact factor: 44.544

Review 7.  Spectrum of malignant renal and urinary bladder tumors on 18F-FDG PET/CT: a pictorial essay.

Authors:  William Makis; Anthony Ciarallo; Rajan Rakheja; Stephan Probst; Marc Hickeson; Christopher Rush; Javier-A Novales-Diaz; Vilma Derbekyan; Jerry Stern; Robert Lisbona
Journal:  Clin Imaging       Date:  2012-06-08       Impact factor: 1.605

8.  Positron emission tomography with L-methyl-11C-methionine in the monitoring of therapy response in muscle-invasive transitional cell carcinoma of the urinary bladder.

Authors:  H Letocha; H Ahlström; P U Malmström; J E Westlin; K J Fasth; S Nilsson
Journal:  Br J Urol       Date:  1994-12

Review 9.  Imaging management of incidentally detected small renal masses.

Authors:  V Anik Sahni; Stuart G Silverman
Journal:  Semin Intervent Radiol       Date:  2014-03       Impact factor: 1.513

Review 10.  Frontiers in clinical and molecular diagnostics and staging of metastatic clear cell renal cell carcinoma.

Authors:  Anna M Czarnecka; Anna Kornakiewicz; Wojciech Kukwa; Cezary Szczylik
Journal:  Future Oncol       Date:  2014-05       Impact factor: 3.404
View more
  6 in total

Review 1.  Molecular Imaging for Evaluation of Viable Testicular Cancer Nodal Metastases.

Authors:  Gregory A Joice; Steven P Rowe; Michael A Gorin; Phillip M Pierorazio
Journal:  Curr Urol Rep       Date:  2018-11-09       Impact factor: 3.092

Review 2.  Current Concepts in the Management of Muscle Invasive Bladder Cancer.

Authors:  Suprita R Krishna; Badrinath R Konety
Journal:  Indian J Surg Oncol       Date:  2016-12-15

3.  PET/CT imaging of renal cell carcinoma with (18)F-VM4-037: a phase II pilot study.

Authors:  Baris Turkbey; Maria L Lindenberg; Stephen Adler; Karen A Kurdziel; Yolanda L McKinney; Juanita Weaver; Cathy D Vocke; Miriam Anver; Gennady Bratslavsky; Philip Eclarinal; Gideon Kwarteng; Frank I Lin; Nana Yaqub-Ogun; Maria J Merino; W Marston Linehan; Peter L Choyke; Adam R Metwalli
Journal:  Abdom Radiol (NY)       Date:  2016-01

4.  Nanotechnology and cancer: improving real-time monitoring and staging of bladder cancer with multimodal mesoporous silica nanoparticles.

Authors:  Sean K Sweeney; Yi Luo; Michael A O'Donnell; Jose Assouline
Journal:  Cancer Nanotechnol       Date:  2016-04-27

Review 5.  The Place of FDG PET/CT in Renal Cell Carcinoma: Value and Limitations.

Authors:  Yiyan Liu
Journal:  Front Oncol       Date:  2016-09-06       Impact factor: 6.244

Review 6.  Carbon-11 and Fluorine-18 Labeled Amino Acid Tracers for Positron Emission Tomography Imaging of Tumors.

Authors:  Aixia Sun; Xiang Liu; Ganghua Tang
Journal:  Front Chem       Date:  2018-01-15       Impact factor: 5.221
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.